New drug aims to ease painful side effects of anal cancer therapy
NCT ID NCT03386500
First seen Jan 29, 2026 · Last updated May 10, 2026 · Updated 13 times
Summary
This study tests a new drug called BMX-001 added to standard radiation and chemotherapy for people newly diagnosed with anal cancer. The goal is to see if BMX-001 can reduce severe side effects like rectal bleeding and skin damage while still fighting the cancer. About 24 adults will take part to find the safest dose and measure quality of life improvements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION EXPOSURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.